Nanoscale drug delivery platforms can provide an attractive therapeutic strategy for cancer treatments, as they can substantially reduce the adverse side effects associated with toxic small-molecule anticancer agents. For enhanced therapeutic efficacy to be achieved with such platforms, a tumor-specific drug-release trigger is a critical requirement. This article reports the use of a pH-sensitive polymer network that surrounds a nanoscale liposome core to trigger the release of both encapsulated hydrophilic, membrane-impermeable Ni(II) cations and amphipathic, membrane-permeable As(III) anticancer agents under acidic conditions commonly encountered in hypoxic tumor tissues and late endosomes. Computational modeling studies provide clear evidence that the acid-triggered drug-release mechanism for this polymer-caged nanobin (PCN) platform arises from a pH- and temperature-responsive conformation change of the cross-linked polymer cage. As a result, the simultaneous release of both of the active agents in this multicomponent therapeutic enhances the pro-apoptotic activity of As(III) while diminishing its acute toxicity, potentially reducing the undesirable side effects commonly associated with this free drug. The ability to engender acid-triggered release of drugs co-encapsulated inside a liposomal template makes drug delivery using PCN an attractive strategy for triggered drug release.
Nanoscale drug delivery platforms can provide an attractive therapeutic strategy for pan class="Disease">cancer treatments, as they can substantially reduce the adverse side effects associated with toxic small-molecule anticancer agents. For enhanced therapeutic efficacy to be achieved with such platforms, a tumor-specific drug-release trigger is a critical requirement. This article reports the use of a pH-sensitive polymer network that surrounds a nanoscale liposome core to trigger the release of both encapsulated hydrophilic, membrane-impermeable Ni(II) cations and amphipathic, membrane-permeable As(III) anticancer agents under acidic conditions commonly encountered in hypoxic tumor tissues and late endosomes. Computational modeling studies provide clear evidence that the acid-triggered drug-release mechanism for this polymer-caged nanobin (PCN) platform arises from a pH- and temperature-responsive conformation change of the cross-linked polymer cage. As a result, the simultaneous release of both of the active agents in this multicomponent therapeutic enhances the pro-apoptotic activity of As(III) while diminishing its acute toxicity, potentially reducing the undesirable side effects commonly associated with this free drug. The ability to engender acid-triggered release of drugs co-encapsulated inside a liposomal template makes drug delivery using PCN an attractive strategy for triggered drug release.
Authors: Richard W Ahn; Feng Chen; Haimei Chen; Stephan T Stern; Jeffrey D Clogston; Anil K Patri; Meera R Raja; Elden P Swindell; Vamsi Parimi; Vincent L Cryns; Thomas V O'Halloran Journal: Clin Cancer Res Date: 2010-06-02 Impact factor: 12.531
Authors: Haimei Chen; Samuel Pazicni; Nancy L Krett; Richard W Ahn; James E Penner-Hahn; Steven T Rosen; Thomas V O'Halloran Journal: Angew Chem Int Ed Engl Date: 2009 Impact factor: 15.336
Authors: Bong Jin Hong; Elden P Swindell; Keith W Macrenaris; Patrick L Hankins; Anthony J Chipre; Daniel J Mastarone; Richard W Ahn; Thomas J Meade; Thomas V O'Halloran; Sonbinh T Nguyen Journal: Part Part Syst Charact Date: 2013-09 Impact factor: 3.310
Authors: Bong Jin Hong; Aysenur Iscen; Anthony J Chipre; Mei Mei Li; One-Sun Lee; Joshua N Leonard; George C Schatz; SonBinh T Nguyen Journal: J Phys Chem Lett Date: 2018-02-19 Impact factor: 6.475
Authors: Elden P Swindell; Patrick L Hankins; Haimei Chen; Denana U Miodragović; Thomas V O'Halloran Journal: Inorg Chem Date: 2013-10-22 Impact factor: 5.165